A methanol extract of Combretum erythrophyllum showed inhibitory bioactivities in a yeast-based microtiter assay for DNA-damaging agents. Bioassay-guided fractionation of this extract yielded two known bioactive compounds, combretastatin A-1 and (−)-combretastatin, and two new bioactive glucosides, combretastatin A-1 2‘-β-d-glucoside (1) and combretastatin B-1 2‘-β-d-glucoside (2). The structures of the new compounds were assigned by 1H and 13C NMR, DEPT, HMQC, and HMBC spectra.
combretastatin A, combretastatin B, Combretum erythrophyllum, DNA damage inhibition
NCBI PubMed ID: 10785413Publication DOI: 10.1021/np9904410Journal NLM ID: 7906882Publisher: American Society of Pharmacognosy
Correspondence: dkingston@vt.edu
Institutions: Department of Chemistry, Virginia Polytechnic Institute and State University, Blacksburg, USA, Research and Development, SmithKline Beecham Pharmaceuticals, King of Prussia, USA
Found